DOUGLAS BYRD: Open Payments
NPI 1477679736 · JACKSON, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$546 in 30 payments from 10 companies in 2025. Trend: 2023 $1,222 · 2024 $716 · 2025 $546
Food & beverage: $546
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $219 |
| Vanda Pharmaceuticals Inc. | 4 | $111 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $43 |
| Corium, LLC | 2 | $40 |
| Otsuka America Pharmaceutical, Inc. | 2 | $40 |
| Axsome Therapeutics, Inc. | 1 | $24 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $23 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $18 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
Products named: VRAYLAR, FANAPT, TRINTELLIX, Azstarys, REXULTI, Auvelity, CAPLYTA, Qelbree.
Industry payments across MS — which companies pay providers there.
